Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
6.06
+0.18 (3.06%)
At close: Jun 6, 2025, 4:00 PM
6.02
-0.04 (-0.66%)
After-hours: Jun 6, 2025, 6:40 PM EDT

Company Description

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.

It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.

Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Tenax Therapeutics, Inc.
Tenax Therapeutics logo
Country United States
Founded 1967
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Christopher Giordano

Contact Details

Address:
101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
United States
Phone 919 855 2100
Website tenaxthera.com

Stock Details

Ticker Symbol TENX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000034956
CUSIP Number 88032L209
ISIN Number US88032L6056
Employer ID 26-2593535
SIC Code 2834

Key Executives

Name Position
Christopher T. Giordano Chief Executive Officer, President and Director
Dr. Stuart Rich M.D. Chief Medical Officer and Director
Thomas A. McGauley Interim Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer
Doug Randall Chief Business Officer
Dr. Douglas Hay Ph.D. Executive Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
May 15, 2025 SCHEDULE 13G/A Filing
May 15, 2025 SCHEDULE 13G Filing
May 14, 2025 10-Q Quarterly Report
May 14, 2025 8-K Current Report
May 14, 2025 SCHEDULE 13G/A Filing
Apr 25, 2025 ARS Filing
Apr 25, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 23, 2025 EFFECT Notice of Effectiveness
Apr 23, 2025 424B3 Prospectus